ArticleJournal of medical microbiology2020
Article in Journal of medical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- The gut reservoir of carbapenem-resistant Enterobacterales: from dysbiosis and colonization to infection and decolonization, with a focus on patients with hematologic malignancies - a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Gut Virome and Aging: Phage-Driven Microbial Stability and Immune Modulation.Aging and disease · 2025Review
- Diagnosing and engineering gut microbiomes.EMBO molecular medicine · 2024Review
- Isolation and Characterization of Novel Lytic Bacteriophages Infecting Carbapenem-Resistant Pathogenic Diarrheagenic and UropathogenicInfection and drug resistance · 2024Article
- Genome analysis of triple phages that curtails MDR E. coli with ML based host receptor prediction and its evaluation.Scientific reports · 2023Article
- The Role of Bacteriophages in the Gut Microbiota: Implications for Human Health.Pharmaceutics · 2023Review
- Insights on Current Strategies to Decolonize the Gut from Multidrug-Resistant Bacteria: Pros and Cons.Antibiotics (Basel, Switzerland) · 2023Article
- The Post-Antibiotic Era: A New Dawn for Bacteriophages.Biology · 2023Review
- Translating phage therapy into the clinic: Recent accomplishments but continuing challenges.PLoS biology · 2023Article
- Characteristics of a novel temperate bacteriophage against Staphylococcus arlettae (vB_SarS_BM31).International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- Review
- The Use of Natural Methods to Control Foodborne Biofilms.Pathogens (Basel, Switzerland) · 2022Review
- Travel-related gastrointestinal diseases: Assessment and management.Public health challenges · 2022Review
- The gut virome: A new microbiome component in health and disease.EBioMedicine · 2022Review
- Isolation, characterization, and comparative genomic analysis of vB_PlaM_Pd22F, a new bacteriophage of the family Myoviridae.Archives of virology · 2022Article
- Impact of Phage Therapy on Multidrug-ResistantMicroorganisms · 2021Article
- Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens.Antibiotics (Basel, Switzerland) · 2021Review
- Phage Therapy in Gastrointestinal Diseases.Microorganisms · 2020Review
- Article
- Novel technologies to characterize and engineer the microbiome in inflammatory bowel disease.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.